# A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

> **NCT06659549** · PHASE2 · RECRUITING · sponsor: **Galimedix Therapeutics Inc** · enrollment: 110 (estimated)

## Conditions studied

- Geographic Atrophy of the Macula

## Interventions

- **DRUG:** GAL-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06659549
- **Lead sponsor:** Galimedix Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659549, "A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06659549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*